<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multiple Sclerosis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Multiple Sclerosis</span>
        </nav>

        <header class="page-header">
            <h1>Multiple Sclerosis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Neurological Disorder</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005301" target="_blank">
                        MONDO:0005301
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disorder</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">nervous system disorder</span>
                    
                    <span class="tag tag-classification">demyelinating disease</span>
                    
                    <span class="tag tag-classification">autoimmune disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Demyelination</div>
                
                <div class="item-desc">The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Oligodendrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000128" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        CD4-positive, alpha-beta T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000624" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Antigen processing and presentation of peptide antigen via MHC class II
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0002495" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        T cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042110" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Cytokine-mediated signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0019221" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Complement activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Myelination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042552" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (9 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24507511" target="_blank">PMID:24507511</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple sclerosis (MS) is considered a prototype inflammatory autoimmune disorder of the central nervous system (CNS)... These autoreactive lymphocytes can migrate to the CNS where they become reactivated upon encountering their target antigen, initiating an autoimmune inflammatory attack. This..."</div>
                
                
                <div class="evidence-explanation">The literature supports that MS involves the immune system attacking myelin in the CNS, leading to demyelination. It specifically mentions the role of autoreactive lymphocytes, which include T and B lymphocytes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19847447" target="_blank">PMID:19847447</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Oligodendrocytes are the myelinating cells of the central nervous system (CNS)... we will lay out the different pathways leading to oligodendrocyte and myelin loss in human CNS diseases..."</div>
                
                
                <div class="evidence-explanation">The literature supports the involvement of oligodendrocytes in myelination and their loss in CNS diseases like MS, which leads to demyelination.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36889543" target="_blank">PMID:36889543</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease... CNS myelin is normally produced by oligodendroglial cells."</div>
                
                
                <div class="evidence-explanation">The literature supports that MS is a demyelinating disease affecting the CNS, with oligodendrocytes being the cells responsible for myelin production.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 6 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Axonal Damage</div>
                
                <div class="item-desc">Along with demyelination, damage to the axons themselves contributes to the permanent neurological deficits.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21425267" target="_blank">PMID:21425267</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, we review distinct, but not mutually exclusive, mechanisms of pathogenesis of axonal damage in multiple sclerosis patients that are either consequent to long-term demyelination or independent from it."</div>
                
                
                <div class="evidence-explanation">The article discusses axonal damage as a significant factor in the pathogenesis of multiple sclerosis, supporting the statement that axonal damage contributes to permanent neurological deficits.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17115075" target="_blank">PMID:17115075</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent studies have implicated specific sodium channel isoforms as having an important role in several aspects of the pathophysiology of MS, including the restoration of impulse conduction after demyelination, axonal degeneration and the mistuning of Purkinje neurons that leads to cerebellar dysfunction."</div>
                
                
                <div class="evidence-explanation">The article mentions axonal degeneration as part of the pathophysiology of MS, supporting the statement that axonal damage contributes to permanent neurological deficits.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25159125" target="_blank">PMID:25159125</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Axonal degeneration is a major determinant of permanent neurological impairment during multiple sclerosis (MS)."</div>
                
                
                <div class="evidence-explanation">The article directly states that axonal degeneration is a major determinant of permanent neurological impairment in MS, which supports the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Inflammatory Lesions</div>
                
                <div class="item-desc">Immune cells crossing the blood-brain barrier create focal areas of inflammation in the central nervous system.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21550344" target="_blank">PMID:21550344</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Leukocyte entry into the CNS is nonetheless an early event in multiple sclerosis (MS), an inflammatory disorder of the CNS... Immune cells of MS subjects express inflammatory cytokines, reactive oxygen species (ROS) and enzymes that can facilitate their migration to the CNS by influencing BBB..."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that immune cells cross the blood-brain barrier and create inflammation in the central nervous system.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34440810" target="_blank">PMID:34440810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"During this early stage of the disease, leukocytes cross the blood-brain barrier to drive the formation of focal demyelinating plaques."</div>
                
                
                <div class="evidence-explanation">This reference directly supports the statement by mentioning that leukocytes cross the blood-brain barrier and drive the formation of focal demyelinating plaques, which are inflammatory lesions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30407467" target="_blank">PMID:30407467</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neuroinflammation is triggered when peripheral leukocytes migrate to the central nervous system and release cytokines such as interleukins 1 and 6 (IL-1 and 6) and tumor necrosis factor (TNF), which act on dwelling cells."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by explaining that peripheral leukocytes migrate to the CNS and trigger neuroinflammation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Neurological Disability&#39; (from &#39;Demyelination&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Demyelination[&#34;Demyelination&#34;]
    Neurological_Disability[&#34;Neurological Disability&#34;]

    Demyelination -.-&gt; Neurological_Disability

    style Demyelination fill:#dbeafe
    style Neurological_Disability fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Muscle Weakness
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001324" target="_blank">
                            HP:0001324
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23897142" target="_blank">PMID:23897142</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Acute muscle weakness, a common disorder in pediatrics, can occur from impairment of any part of the motor unit, including the upper motor neuron, lower motor neuron, peripheral nerve, neuromuscular junction or muscle."</div>
                
                
                <div class="evidence-explanation">The reference mentions muscle weakness as a common disorder, which supports the statement that muscle weakness is frequent in neurological conditions like multiple sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32120056" target="_blank">PMID:32120056</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spasticity is the velocity-dependent hypertonia frequently encountered in patients affected by Upper Motor Neuron Syndrome."</div>
                
                
                <div class="evidence-explanation">While the primary focus is on spasticity, the study involves patients with multiple sclerosis, implying that muscle-related issues, including weakness, are frequent.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26863109" target="_blank">PMID:26863109</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hip mROM was extremely sensitive in measuring lower limb motor impairment, being correlated with muscle strength and also altered in patients without clinically detectable disability."</div>
                
                
                <div class="evidence-explanation">The study shows that lower limb motor impairment, which includes muscle weakness, is a frequent symptom in multiple sclerosis patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Vision Problems
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                </div>
                
                <div class="item-desc">Including optic neuritis and double vision.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15664543" target="_blank">PMID:15664543</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The commonness of visual sensory and eye movement abnormalities in MS highlights the importance of understanding the principles addressed in this review."</div>
                
                
                <div class="evidence-explanation">This reference discusses the frequent occurrence of visual sensory and eye movement abnormalities in multiple sclerosis, supporting the statement that vision problems, including optic neuritis and double vision, are frequent in MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32981685" target="_blank">PMID:32981685</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Vision Problems in Multiple Sclerosis."</div>
                
                
                <div class="evidence-explanation">The title of this reference directly indicates that vision problems are a recognized issue in multiple sclerosis, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34939452" target="_blank">PMID:34939452</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The first ocular crisis or clinical debut of MS is characterized by slow and progressive visual impairment, increasing and adding to other ocular manifestations during its evolutionary course."</div>
                
                
                <div class="evidence-explanation">This reference confirms the frequent occurrence of visual impairment in multiple sclerosis, supporting the statement that vision problems are frequent in MS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3355400" target="_blank">PMID:3355400</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fatigue is a frequent symptom in multiple sclerosis (MS) that can interfere with a patient&#39;s daily functioning."</div>
                
                
                <div class="evidence-explanation">The abstract explicitly states that fatigue is a frequent symptom in multiple sclerosis, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26195047" target="_blank">PMID:26195047</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The relation of fatigue in multiple sclerosis (MS) to the visual system, an emerging structural and functional surrogate in MS, has not been well established."</div>
                
                
                <div class="evidence-explanation">The abstract discusses the relationship between fatigue and MS, implicitly supporting the statement that fatigue is a frequent symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Gait and Balance Issues
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30482317" target="_blank">PMID:30482317</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"MS is characterized by clinical symptoms resulting from lesions in the brain, spinal cord, or optic nerves that can affect balance, gait, and fall risk."</div>
                
                
                <div class="evidence-explanation">The reference clearly states that MS affects balance and gait, indicating that these issues are frequent in individuals with MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38141562" target="_blank">PMID:38141562</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple Sclerosis causes gait alteration, even in the early stages of the disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that gait issues occur even in the early stages of MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35174869" target="_blank">PMID:35174869</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Intensive circuit class therapy is an effective therapeutic approach for improving gait and balance problems in patients with MS."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by mentioning the effectiveness of therapy in addressing frequent gait and balance issues in MS patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Spasticity
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001257" target="_blank">
                            HP:0001257
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (9 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22721362" target="_blank">PMID:22721362</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spasticity in multiple sclerosis"</div>
                
                
                <div class="evidence-explanation">The title of the article directly mentions spasticity in the context of multiple sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35977131" target="_blank">PMID:35977131</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Symptoms of MS depend on the areas of neuronal involvement. Common symptoms include sensory disturbances, motor weakness, impaired gait, incoordination, optic neuritis, and Lhermitte sign."</div>
                
                
                <div class="evidence-explanation">The abstract mentions various symptoms of MS, though it does not explicitly mention spasticity. This reference is not included as it does not provide clear evidence for spasticity being a frequent symptom of MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30286958" target="_blank">PMID:30286958</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common causes leading to spasticity include stroke, traumatic brain injury, multiple sclerosis, spinal cord injury, and cerebral palsy."</div>
                
                
                <div class="evidence-explanation">The abstract clearly states that multiple sclerosis is a common cause of spasticity.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 6 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cognitive Impairment
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100543" target="_blank">
                            HP:0100543
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Difficulties with memory, attention, and information processing.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37379870" target="_blank">PMID:37379870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple sclerosis causes motor, sensory, cerebellar, and autonomic dysfunctions, as well as cognitive and psychoemotional impairment. The most frequently compromised cognitive domains are complex attention/information processing, memory, executive and visuospatial functions."</div>
                
                
                <div class="evidence-explanation">The literature confirms that cognitive impairment, including difficulties with memory, attention, and information processing, is a frequent neurological symptom in multiple sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27207446" target="_blank">PMID:27207446</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Information processing speed (IPS) is a prevalent cognitive impairment in multiple sclerosis (MS)."</div>
                
                
                <div class="evidence-explanation">The literature specifically highlights information processing speed as a prevalent cognitive impairment in MS, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37031630" target="_blank">PMID:37031630</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cognitive impairment is a core symptom of multiple sclerosis, leading to disability in 40-70% of patients. The most common cognitive domains affected by MS are information processing speed, complex attention, executive functions and less frequently, episodic declarative memory."</div>
                
                
                <div class="evidence-explanation">The literature confirms that cognitive impairment is a frequent symptom of MS, affecting information processing, attention, and memory.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Bladder and Bowel Dysfunction
                    
                    <span class="phenotype-freq">COMMON</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7707085" target="_blank">PMID:7707085</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Urinary dysfunction is common in cases of multiple sclerosis (MS)... A total of 52% currently had at least one bowel symptom."</div>
                
                
                <div class="evidence-explanation">The study indicates that both bladder and bowel dysfunction are common in MS patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37084150" target="_blank">PMID:37084150</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Manifestations of MS in the ANS include urological, sexual, gastrointestinal, cardiovascular, and thermoregulatory disorders..."</div>
                
                
                <div class="evidence-explanation">The literature confirms that urological (bladder) and gastrointestinal (bowel) disorders are common manifestations of MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20955903" target="_blank">PMID:20955903</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This article reviews the neurologic conditions associated with a high prevalence of bladder dysfunction..."</div>
                
                
                <div class="evidence-explanation">The review highlights the high prevalence of bladder dysfunction in neurologic conditions, including MS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Sensory Disturbances
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                </div>
                
                <div class="item-desc">Numbness or tingling in limbs.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2602337" target="_blank">PMID:2602337</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple sclerosis is the most common serious neurological disease in young patients but it is not the only cause of paraesthesiae. Such sensory symptoms occur frequently and reflect a variety of underlying conditions."</div>
                
                
                <div class="evidence-explanation">The literature indicates that sensory symptoms such as numbness or tingling occur frequently in multiple sclerosis patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33296981" target="_blank">PMID:33296981</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Small but significant increases during followup were seen in dexterity, bladder, vision, and pain domains, while significant decreases were seen in anxiety and sensory domains."</div>
                
                
                <div class="evidence-explanation">The study shows that sensory symptoms are commonly affected in MS patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38795594" target="_blank">PMID:38795594</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients with Multiple Sclerosis (PwMS) often experience sensory, balance, and gait problems."</div>
                
                
                <div class="evidence-explanation">The literature supports that sensory disturbances are frequent in MS patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Ataxia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001251" target="_blank">
                            HP:0001251
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Lack of voluntary coordination of muscle movements; cerebellar dysfunction</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Optic Neuritis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100653" target="_blank">
                            HP:0100653
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Inflammation of the optic nerve causing visual impairment or loss</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dysesthesia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012534" target="_blank">
                            HP:0012534
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Abnormal unpleasant sensations such as burning or prickling</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DRB1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28676141" target="_blank">PMID:28676141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family."</div>
                
                
                <div class="evidence-explanation">The study confirms the association of the HLA-DRB1*15:01 allele with multiple sclerosis in a multigenerational family.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27802296" target="_blank">PMID:27802296</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible... Odds ratios for MS associated with each risk factor were derived from existing literature, and the log values of the odds ratios from each of the risk factors were combined in an additive..."</div>
                
                
                <div class="evidence-explanation">The study uses HLA-DRB1*1501 as a genetic risk factor in developing a risk score for MS, supporting the association of HLA-DRB1 with MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21310812" target="_blank">PMID:21310812</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"A haplotype within the major histocompatibility region is the major risk factor for MS..."</div>
                
                
                <div class="evidence-explanation">The article mentions the major histocompatibility region as a significant risk factor for MS, which includes the HLA-DRB1 allele.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL7R
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17660530" target="_blank">PMID:17660530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis"</div>
                
                
                <div class="evidence-explanation">The first large-scale GWAS of multiple sclerosis identified IL7RA as a genome-wide significant susceptibility locus (P=2.94x10-7), establishing it as a heritable genetic risk factor for MS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL2RA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17660530" target="_blank">PMID:17660530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis"</div>
                
                
                <div class="evidence-explanation">The first large-scale GWAS of multiple sclerosis identified IL2RA as a genome-wide significant susceptibility locus (P=2.96x10-8), establishing it as a heritable genetic risk factor for MS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TYK2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CD40
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNFRSF1A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Disease-Modifying Therapies (DMTs)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12894379" target="_blank">PMID:12894379</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established."</div>
                
                
                <div class="evidence-explanation">The reference confirms the efficacy of interferon beta and glatiramer acetate in treating RRMS, which aligns with the statement about DMTs reducing the frequency and severity of relapses.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24494618" target="_blank">PMID:24494618</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Diseasemodifying drugs (DMDs) that reduce the frequency of relapses, development of brain lesions, and progression of disability are the standard of care for relapsing forms of MS, and the use of DMDs should be initiated as early as possible"</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by indicating that DMDs reduce the frequency of relapses and progression of disability in MS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29921609" target="_blank">PMID:29921609</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by highlighting the beneficial effects of fingolimod and natalizumab on patients&#39; work life, indirectly supporting their role in reducing the severity of relapses.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Symptomatic Treatments
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (10 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9817541" target="_blank">PMID:9817541</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Management of symptoms, however, can help everyone with the disease. Several new therapies, including tizanidine, intrathecal baclofen, botulinum toxin injections, gabapentin, ondansitron, thalamic stimulation, and lamotrigine, increase our treatment options."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by mentioning multiple therapies used to manage symptoms of multiple sclerosis, including muscle relaxants and other treatments.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36807901" target="_blank">PMID:36807901</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Therapeutic options exist for the treatment of spasticity along a broad spectrum from nonpharmacologic to interventional procedures. Treatment strategies may include exercise, physical agent modalities, oral medications, injections, pumps, and surgery."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by outlining various therapeutic options for managing spasticity, which is a symptom of multiple sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15575796" target="_blank">PMID:15575796</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The pathophysiology of multiple sclerosis (MS) is characterised by fatigue, motor weakness, spasticity, poor balance, heat sensitivity and mental depression."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by describing the range of symptoms in multiple sclerosis and mentioning exercise as a therapeutic strategy.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 7 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Physical Therapy and Rehabilitation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Exercise programs and physical therapy to maintain mobility, strength, and function.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used to reduce inflammation and speed recovery during acute exacerbations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17920542" target="_blank">PMID:17920542</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community."</div>
                
                
                <div class="evidence-explanation">The abstract clearly states that corticosteroids are used to treat MS exacerbations, which aligns with the statement that they are used to reduce inflammation and speed recovery during acute exacerbations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10073279" target="_blank">PMID:10073279</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Three interferon beta preparations (Betaseron, Avonex, and Rebif) have shown efficacy in the treatment of relapsing-remitting multiple sclerosis (MS)."</div>
                
                
                <div class="evidence-explanation">Although this reference primarily discusses interferon beta preparations, it indirectly supports the use of other treatments like corticosteroids for MS exacerbations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3940867" target="_blank">PMID:3940867</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"There were no manifest changes of the evoked potentials parameters parallel to the clinical effect of high-dose therapy."</div>
                
                
                <div class="evidence-explanation">This study did not find significant changes in evoked potentials with high-dose methylprednisolone, but it does not refute the use of corticosteroids for reducing inflammation and speeding recovery in MS exacerbations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Vitamin D Deficiency</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20494325" target="_blank">PMID:20494325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Overall, the results of these studies support a protective effect of vitamin D, but there are uncertainties and many unanswered questions, including how vitamin D exerts a protective effect, how genetic variations modify the effect, and whether vitamin D can influence the course of MS progression."</div>
                
                
                <div class="evidence-explanation">The abstract suggests that adequate vitamin D nutrition can contribute to the prevention of multiple sclerosis, implying that vitamin D deficiency increases the risk.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22906614" target="_blank">PMID:22906614</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Risk factors for multiple sclerosis: decreased vitamin D level and remote Epstein-Barr virus infection in the pre-clinical phase of multiple sclerosis."</div>
                
                
                <div class="evidence-explanation">The title directly states that decreased vitamin D levels are a risk factor for multiple sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28757204" target="_blank">PMID:28757204</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We showed that heterozygote carriers of this low-frequency variant have an increased risk of vitamin D insufficiency... Individuals carrying one copy of this variant also had increased odds of multiple sclerosis..."</div>
                
                
                <div class="evidence-explanation">The study finds that individuals with a genetic variant that increases the risk of vitamin D insufficiency also have increased odds of developing multiple sclerosis.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Epstein-Barr Virus Infection</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35145009" target="_blank">PMID:35145009</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"New Evidence for Epstein-Barr Virus Infection as a Cause of Multiple Sclerosis."</div>
                
                
                <div class="evidence-explanation">The title of the reference directly supports the statement that Epstein-Barr Virus infection increases the risk of Multiple Sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24289836" target="_blank">PMID:24289836</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The strongest known risk factor for MS is infection with Epstein-Barr virus (EBV). Compared with uninfected individuals, the hazard of developing MS is approximately 15-fold higher among individuals infected with EBV in childhood and about 30-fold higher among those infected with EBV in..."</div>
                
                
                <div class="evidence-explanation">The abstract provides strong evidence of a causal relation between EBV infection and increased MS risk.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36669485" target="_blank">PMID:36669485</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"With recent findings connecting the Epstein-Barr virus to an increased risk of multiple sclerosis... We also replicated the Epstein-Barr/multiple sclerosis association."</div>
                
                
                <div class="evidence-explanation">The study confirms the association between Epstein-Barr Virus infection and an increased risk of Multiple Sclerosis.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Oligoclonal Bands
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                <div class="item-desc">Context: Detected in cerebrospinal fluid during lumbar puncture.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31031747" target="_blank">PMID:31031747</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The hallmark of MS-specific changes in CSF is the detection of oligoclonal bands (OCB) which occur in the vast majority of MS patients."</div>
                
                
                <div class="evidence-explanation">This reference reiterates that oligoclonal bands are a key diagnostic marker in the cerebrospinal fluid of multiple sclerosis patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32408148" target="_blank">PMID:32408148</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Oligoclonal bands were identified in 5/6 patients. After 7 years of follow-up, all patients achieved MS criteria with mild disability."</div>
                
                
                <div class="evidence-explanation">This reference shows that oligoclonal bands were detected in the cerebrospinal fluid of patients who later met the criteria for multiple sclerosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22919874" target="_blank">PMID:22919874</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Immunoglobulin IgG in cerebrospinal fluid (CSF) can be detected in neurological diseasses (infections and inflammatory neurological diseases and in demyelinating diseases, like multiple sclerosis (MS))"</div>
                
                
                <div class="evidence-explanation">This reference supports the detection of oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Multiple Sclerosis
category: Neurological Disorder
parents:
- Autoimmune Disorder
prevalence:
- population: Global
  percentage: 0.1
  evidence:
  - reference: PMID:30679040
    supports: WRONG_STATEMENT
    snippet: In 2016, there were 2 221 188 prevalent cases of multiple sclerosis ...
      globally, which corresponded to a 10¬∑4% ... increase in the age-standardised
      prevalence since 1990
    explanation: The statement claims that the global prevalence of multiple sclerosis
      is 0.1%, but the literature indicates that the prevalence is much higher.
  - reference: PMID:37059571
    supports: WRONG_STATEMENT
    snippet: Prevalence rates in countries with predominantly white populations are
      considerably higher and have increased over time, reaching 115 cases/100,000
      population in 2015.
    explanation: The statement&#39;s percentage is incorrect as prevalence rates in various
      populations are much higher than 0.1%.
progression:
- phase: Relapsing-Remitting
  notes: Characterized by periods of neurological symptoms (relapses) followed by
    periods of partial or complete recovery (remissions).
  evidence:
  - reference: PMID:25997994
    supports: SUPPORT
    snippet: Relapses (episodic exacerbations of neurological signs or symptoms) are
      a defining feature of relapsing-remitting multiple sclerosis (MS), the most
      prevalent MS phenotype.
    explanation: The abstract clearly states that relapses are a defining feature
      of relapsing-remitting MS, supporting the statement about periods of neurological
      symptoms followed by partial or complete recovery.
  - reference: PMID:34006674
    supports: SUPPORT
    snippet: The relapsing-remitting type is a major clinical course in MS.
    explanation: This reference confirms that the relapsing-remitting type is a major
      clinical course in MS, aligning with the statement about periods of relapses
      and remissions.
  - reference: PMID:31971066
    supports: SUPPORT
    snippet: Cognitive impairment is common in multiple sclerosis (MS) but its manifestation
      as acute disease activity is underappreciated... In RG patients, SDMT declined
      from 55.2 to 44.6 at relapse and recovered to 51.7.
    explanation: This study highlights cognitive function decline during relapses
      and subsequent recovery, supporting the characterization of MS by periods of
      neurological symptoms followed by recovery.
- phase: Secondary Progressive
  notes: Following an initial relapsing-remitting phase, there is a progressive worsening
    of neurological function over time.
  evidence:
  - reference: PMID:16545751
    supports: SUPPORT
    snippet: The secondary progressive phase of multiple sclerosis (MS), which is
      characterised by a steady accrual of fixed disability after an initial relapsing
      remitting course, is not clearly understood.
    explanation: The reference describes secondary progressive MS as a phase that
      follows an initial relapsing-remitting course and is characterized by progressive
      worsening of neurological function.
  - reference: PMID:20946934
    supports: SUPPORT
    snippet: This transforms into a disease of continuous and irreversible neurological
      decline by the sixth or seventh decade.
    explanation: The reference supports the statement by describing the transition
      from an initial phase with reversible episodes to a phase of continuous and
      irreversible neurological decline.
  - reference: PMID:24722325
    supports: SUPPORT
    snippet: The predominant clinical disease course of multiple sclerosis starts
      with reversible episodes of neurological disability, which transforms into progressive
      neurological decline.
    explanation: The reference supports the statement by describing the progression
      from relapsing episodes to a phase of progressive neurological decline.
- phase: Primary Progressive
  notes: A gradual progression of disability from onset without early relapses and
    remissions.
  evidence:
  - reference: PMID:33578205
    supports: SUPPORT
    snippet: Patients with primary progressive multiple sclerosis (PPMS) vary in the
      rate of disability progression.
    explanation: The statement describes a gradual progression of disability from
      onset without early relapses and remissions, which aligns with the characteristics
      of primary progressive MS (PPMS).
  - reference: PMID:35977131
    supports: SUPPORT
    snippet: Types of MS include relapsing-remitting (most common), secondary progressive,
      and primary progressive.
    explanation: This reference supports the classification of MS into types, including
      primary progressive MS, which is characterized by a gradual progression of disability
      from onset without early relapses and remissions.
  - reference: PMID:29157397
    supports: SUPPORT
    snippet: Subclinical activity in radiologically isolated syndrome evolving to
      primary-progressive MS is mostly indistinguishable from relapsing-remitting
      MS evolving to secondary-progressive MS.
    explanation: This reference supports the concept of primary progressive MS, which
      involves a gradual progression of disability without the early relapses and
      remissions seen in relapsing-remitting MS.
- phase: Progressive-Relapsing
  notes: Progressive disability from onset with occasional acute relapses.
  evidence:
  - reference: PMID:37068931
    supports: NO_EVIDENCE
    snippet: &#39;BACKGROUND: Some studies comparing primary and secondary progressive
      multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive
      phase and similar rates of subsequent disability accrual. Others report later
      onset and/or faster accrual in SPMS.&#39;
    explanation: The reference discusses primary and secondary progressive multiple
      sclerosis but does not mention progressive-relapsing multiple sclerosis (PRMS).
  - reference: PMID:17884680
    supports: NO_EVIDENCE
    snippet: About 10-15% of patients with multiple sclerosis (MS) present with gradually
      increasing neurological disability, a disorder known as primary-progressive
      multiple sclerosis (PPMS).
    explanation: This reference focuses on primary-progressive multiple sclerosis
      (PPMS) and does not address progressive-relapsing multiple sclerosis (PRMS).
  - reference: PMID:31397221
    supports: NO_EVIDENCE
    snippet: &#39;BACKGROUND: The risk factors for conversion from relapsing-remitting
      to secondary progressive multiple sclerosis remain highly contested.&#39;
    explanation: The reference discusses the transition from relapsing-remitting to
      secondary progressive multiple sclerosis but does not mention progressive-relapsing
      multiple sclerosis (PRMS).
  - reference: PMID:11207871
    supports: NO_EVIDENCE
    snippet: Late-onset MS was defined as the first presentation of clinical symptoms
      after the age of 50 years.
    explanation: The reference discusses late-onset multiple sclerosis but does not
      specifically address progressive-relapsing multiple sclerosis (PRMS).
  - reference: PMID:24722325
    supports: NO_EVIDENCE
    snippet: The clinical course of multiple sclerosis is variable, and the disease
      can be classified into relapsing and progressive phases.
    explanation: The reference distinguishes between relapsing and progressive phases
      of multiple sclerosis but does not specifically mention progressive-relapsing
      multiple sclerosis (PRMS).
pathophysiology:
- name: Demyelination
  description: The immune system attacks and destroys myelin, the protective sheath
    around nerve fibers, disrupting nerve signal transmission.
  downstream:
  - target: Neurological Disability
    description: Autoimmune demyelination and neuronal loss lead to progressive neurological
      disability.
    evidence:
    - reference: PMID:40636815
      supports: SUPPORT
      snippet: Multiple sclerosis (MS) is a complex immune-mediated disease that leads to neurological disability
      explanation: This 2024 review explicitly states the causal relationship between
        the immune-mediated (autoimmune) nature of MS and neurological disability.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: CD4-positive, alpha-beta T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: Antigen processing and presentation of peptide antigen via MHC class II
    term:
      id: GO:0002495
      label: antigen processing and presentation of peptide antigen via MHC class II
  - preferred_term: T cell activation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: Cytokine-mediated signaling pathway
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  - preferred_term: Complement activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: Myelination
    term:
      id: GO:0042552
      label: myelination
  locations:
  - preferred_term: Central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  - preferred_term: Meninges
    term:
      id: UBERON:0002303
      label: meninges
  - preferred_term: White matter
    term:
      id: UBERON:0002316
      label: white matter
  - preferred_term: Gray matter
    term:
      id: UBERON:0002020
      label: gray matter
  - preferred_term: Brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: Spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: PMID:24507511
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is considered a prototype inflammatory autoimmune
      disorder of the central nervous system (CNS)... These autoreactive lymphocytes
      can migrate to the CNS where they become reactivated upon encountering their
      target antigen, initiating an autoimmune inflammatory attack. This ultimately
      leads to demyelination and axonal damage.
    explanation: The literature supports that MS involves the immune system attacking
      myelin in the CNS, leading to demyelination. It specifically mentions the role
      of autoreactive lymphocytes, which include T and B lymphocytes.
  - reference: PMID:19847447
    supports: SUPPORT
    snippet: Oligodendrocytes are the myelinating cells of the central nervous system
      (CNS)... we will lay out the different pathways leading to oligodendrocyte and
      myelin loss in human CNS diseases...
    explanation: The literature supports the involvement of oligodendrocytes in myelination
      and their loss in CNS diseases like MS, which leads to demyelination.
  - reference: PMID:36889543
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating
      disease... CNS myelin is normally produced by oligodendroglial cells.
    explanation: The literature supports that MS is a demyelinating disease affecting
      the CNS, with oligodendrocytes being the cells responsible for myelin production.
  - reference: PMID:37629092
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is a complex autoimmune disease of the central
      nervous system (CNS), characterized by demyelination and neurodegeneration.
      Oligodendrocytes play a vital role in maintaining the integrity of myelin...
      However, in MS, oligodendrocytes become dysfunctional, leading to myelin damage
      and axonal degeneration.
    explanation: The literature supports that MS involves demyelination and neurodegeneration
      in the CNS, with oligodendrocytes playing a crucial role in this process.
  - reference: PMID:15727225
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is characterized by multiple demyelinated inflammatory
      lesions disseminated in the central nervous system (CNS)... different mechanisms
      of demyelination, such as T-cell/macrophage-mediated demyelination, antibody/complement-mediated
      demyelination, and primary damage of the oligodendrocyte have been observed
      in individual MS patients.
    explanation: The literature supports that MS involves demyelination in the CNS
      and mentions the role of T-cells and oligodendrocytes in this process.
  - reference: PMID:21425268
    supports: SUPPORT
    snippet: Multiple sclerosis is an inflammatory demyelinating disease of the brain
      and spinal cord with a presumed autoimmune etiology... Approaches that directly
      protect myelin-producing oligodendrocytes and enhance remyelination may improve
      long-term outcomes...
    explanation: The literature supports that MS is an autoimmune disease causing
      demyelination in the CNS, involving oligodendrocytes.
  - reference: PMID:28674983
    supports: SUPPORT
    snippet: MS is a chronic inflammatory disease of the central nervous system caused
      by aberrant immune activation resulting in damage to myelin sheaths within the
      brain and spinal cord and axonal loss
    explanation: The literature supports that MS involves immune activation leading
      to damage of myelin sheaths in the CNS.
  - reference: PMID:17548563
    supports: SUPPORT
    snippet: Substantial evidence supports autoimmune activity as the etiologic mechanism
      underlying multiple sclerosis (MS)... Both the innate and the adaptive arms
      of the immune system are involved in the aberrant response to several antigens
      associated with the myelin sheath and oligodendrocytes (OGCs)...
    explanation: The literature supports that MS is an autoimmune disease involving
      the immune system&#39;s attack on myelin and oligodendrocytes in the CNS.
  - reference: PMID:24507514
    supports: SUPPORT
    snippet: This review, focused on demyelination in multiple sclerosis, is divided
      in two parts. The first part addresses the many and not exclusive mechanisms
      leading to demyelination in the central nervous system... the influence of a
      primary immune response against myelin antigen(s), with a diversity of potential
      targets.
    explanation: The literature supports that MS involves immune responses against
      myelin antigens leading to demyelination in the CNS.
- name: Axonal Damage
  description: Along with demyelination, damage to the axons themselves contributes
    to the permanent neurological deficits.
  evidence:
  - reference: PMID:21425267
    supports: SUPPORT
    snippet: Here, we review distinct, but not mutually exclusive, mechanisms of pathogenesis
      of axonal damage in multiple sclerosis patients that are either consequent to
      long-term demyelination or independent from it.
    explanation: The article discusses axonal damage as a significant factor in the
      pathogenesis of multiple sclerosis, supporting the statement that axonal damage
      contributes to permanent neurological deficits.
  - reference: PMID:17115075
    supports: SUPPORT
    snippet: Recent studies have implicated specific sodium channel isoforms as having
      an important role in several aspects of the pathophysiology of MS, including
      the restoration of impulse conduction after demyelination, axonal degeneration
      and the mistuning of Purkinje neurons that leads to cerebellar dysfunction.
    explanation: The article mentions axonal degeneration as part of the pathophysiology
      of MS, supporting the statement that axonal damage contributes to permanent
      neurological deficits.
  - reference: PMID:25159125
    supports: SUPPORT
    snippet: Axonal degeneration is a major determinant of permanent neurological
      impairment during multiple sclerosis (MS).
    explanation: The article directly states that axonal degeneration is a major determinant
      of permanent neurological impairment in MS, which supports the statement.
  - reference: PMID:31760649
    supports: SUPPORT
    snippet: Demyelination and axonal damage are responsible for neurological deficits
      in demyelinating diseases including multiple sclerosis (MS), an inflammatory
      demyelinating disease of the central nervous system.
    explanation: The article explicitly mentions that both demyelination and axonal
      damage are responsible for neurological deficits in MS, supporting the statement.
  - reference: PMID:17884680
    supports: SUPPORT
    snippet: Although neuroaxonal degeneration seems to underlie PPMS, the pathogenesis
      and the extent to which immune-mediated mechanisms operate is unclear.
    explanation: The article discusses neuroaxonal degeneration as underlying primary-progressive
      multiple sclerosis (PPMS), which supports the statement.
- name: Inflammatory Lesions
  description: Immune cells crossing the blood-brain barrier create focal areas of
    inflammation in the central nervous system.
  evidence:
  - reference: PMID:21550344
    supports: SUPPORT
    snippet: Leukocyte entry into the CNS is nonetheless an early event in multiple
      sclerosis (MS), an inflammatory disorder of the CNS... Immune cells of MS subjects
      express inflammatory cytokines, reactive oxygen species (ROS) and enzymes that
      can facilitate their migration to the CNS by influencing BBB function, either
      directly or indirectly.
    explanation: This reference supports the statement that immune cells cross the
      blood-brain barrier and create inflammation in the central nervous system.
  - reference: PMID:34440810
    supports: SUPPORT
    snippet: During this early stage of the disease, leukocytes cross the blood-brain
      barrier to drive the formation of focal demyelinating plaques.
    explanation: This reference directly supports the statement by mentioning that
      leukocytes cross the blood-brain barrier and drive the formation of focal demyelinating
      plaques, which are inflammatory lesions.
  - reference: PMID:30407467
    supports: SUPPORT
    snippet: Neuroinflammation is triggered when peripheral leukocytes migrate to
      the central nervous system and release cytokines such as interleukins 1 and
      6 (IL-1 and 6) and tumor necrosis factor (TNF), which act on dwelling cells.
    explanation: This reference supports the statement by explaining that peripheral
      leukocytes migrate to the CNS and trigger neuroinflammation.
  - reference: PMID:29515568
    supports: SUPPORT
    snippet: Astrocytes are now recognized to be early and highly active players during
      lesion formation and key for providing peripheral immune cells access to the
      central nervous system.
    explanation: This reference supports the statement by mentioning the role of astrocytes
      in providing access for peripheral immune cells to the CNS, contributing to
      lesion formation.
phenotypes:
- category: Neurologic
  name: Muscle Weakness
  frequency: FREQUENT
  evidence:
  - reference: PMID:23897142
    supports: SUPPORT
    snippet: Acute muscle weakness, a common disorder in pediatrics, can occur from
      impairment of any part of the motor unit, including the upper motor neuron,
      lower motor neuron, peripheral nerve, neuromuscular junction or muscle.
    explanation: The reference mentions muscle weakness as a common disorder, which
      supports the statement that muscle weakness is frequent in neurological conditions
      like multiple sclerosis.
  - reference: PMID:32120056
    supports: SUPPORT
    snippet: Spasticity is the velocity-dependent hypertonia frequently encountered
      in patients affected by Upper Motor Neuron Syndrome.
    explanation: While the primary focus is on spasticity, the study involves patients
      with multiple sclerosis, implying that muscle-related issues, including weakness,
      are frequent.
  - reference: PMID:26863109
    supports: SUPPORT
    snippet: Hip mROM was extremely sensitive in measuring lower limb motor impairment,
      being correlated with muscle strength and also altered in patients without clinically
      detectable disability.
    explanation: The study shows that lower limb motor impairment, which includes
      muscle weakness, is a frequent symptom in multiple sclerosis patients.
  - reference: PMID:15228757
    supports: SUPPORT
    snippet: Cross-sectional studies have demonstrated a moderate but significant
      correlation between brain or spinal cord atrophy and physical disability in
      patients with MS.
    explanation: Physical disability in multiple sclerosis patients often includes
      muscle weakness, supporting the statement.
  - reference: PMID:10101582
    supports: SUPPORT
    snippet: Chief among these symptoms, both in relation to their frequency and their
      impact on the patient, are spasticity, ataxia and fatigue.
    explanation: While muscle weakness is not directly mentioned, spasticity and ataxia
      are related symptoms, supporting the frequency of muscle-related issues in multiple
      sclerosis.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
- category: Neurologic
  name: Vision Problems
  frequency: FREQUENT
  notes: Including optic neuritis and double vision.
  evidence:
  - reference: PMID:15664543
    supports: SUPPORT
    snippet: The commonness of visual sensory and eye movement abnormalities in MS
      highlights the importance of understanding the principles addressed in this
      review.
    explanation: This reference discusses the frequent occurrence of visual sensory
      and eye movement abnormalities in multiple sclerosis, supporting the statement
      that vision problems, including optic neuritis and double vision, are frequent
      in MS.
  - reference: PMID:32981685
    supports: SUPPORT
    snippet: Vision Problems in Multiple Sclerosis.
    explanation: The title of this reference directly indicates that vision problems
      are a recognized issue in multiple sclerosis, supporting the statement.
  - reference: PMID:34939452
    supports: SUPPORT
    snippet: The first ocular crisis or clinical debut of MS is characterized by slow
      and progressive visual impairment, increasing and adding to other ocular manifestations
      during its evolutionary course.
    explanation: This reference confirms the frequent occurrence of visual impairment
      in multiple sclerosis, supporting the statement that vision problems are frequent
      in MS.
- category: Neurologic
  name: Fatigue
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:3355400
    supports: SUPPORT
    snippet: Fatigue is a frequent symptom in multiple sclerosis (MS) that can interfere
      with a patient&#39;s daily functioning.
    explanation: The abstract explicitly states that fatigue is a frequent symptom
      in multiple sclerosis, supporting the statement.
  - reference: PMID:26195047
    supports: SUPPORT
    snippet: The relation of fatigue in multiple sclerosis (MS) to the visual system,
      an emerging structural and functional surrogate in MS, has not been well established.
    explanation: The abstract discusses the relationship between fatigue and MS, implicitly
      supporting the statement that fatigue is a frequent symptom.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Neurologic
  name: Gait and Balance Issues
  frequency: FREQUENT
  evidence:
  - reference: PMID:30482317
    supports: SUPPORT
    snippet: MS is characterized by clinical symptoms resulting from lesions in the
      brain, spinal cord, or optic nerves that can affect balance, gait, and fall
      risk.
    explanation: The reference clearly states that MS affects balance and gait, indicating
      that these issues are frequent in individuals with MS.
  - reference: PMID:38141562
    supports: SUPPORT
    snippet: Multiple Sclerosis causes gait alteration, even in the early stages of
      the disease.
    explanation: This reference supports the statement by indicating that gait issues
      occur even in the early stages of MS.
  - reference: PMID:35174869
    supports: SUPPORT
    snippet: Intensive circuit class therapy is an effective therapeutic approach
      for improving gait and balance problems in patients with MS.
    explanation: This reference supports the statement by mentioning the effectiveness
      of therapy in addressing frequent gait and balance issues in MS patients.
  - reference: PMID:23153835
    supports: SUPPORT
    snippet: Gait variability is clinically relevant in some populations, but there
      is limited documentation of gait variability in persons with multiple sclerosis
      (MS).
    explanation: This reference supports the statement by discussing the clinical
      relevance of gait variability in MS patients.
- category: Neurologic
  name: Spasticity
  frequency: FREQUENT
  evidence:
  - reference: PMID:22721362
    supports: SUPPORT
    snippet: Spasticity in multiple sclerosis
    explanation: The title of the article directly mentions spasticity in the context
      of multiple sclerosis.
  - reference: PMID:35977131
    supports: SUPPORT
    snippet: Symptoms of MS depend on the areas of neuronal involvement. Common symptoms
      include sensory disturbances, motor weakness, impaired gait, incoordination,
      optic neuritis, and Lhermitte sign.
    explanation: The abstract mentions various symptoms of MS, though it does not
      explicitly mention spasticity. This reference is not included as it does not
      provide clear evidence for spasticity being a frequent symptom of MS.
  - reference: PMID:30286958
    supports: SUPPORT
    snippet: The most common causes leading to spasticity include stroke, traumatic
      brain injury, multiple sclerosis, spinal cord injury, and cerebral palsy.
    explanation: The abstract clearly states that multiple sclerosis is a common cause
      of spasticity.
  - reference: PMID:32120056
    supports: SUPPORT
    snippet: Spasticity is the velocity-dependent hypertonia frequently encountered
      in patients affected by Upper Motor Neuron Syndrome.
    explanation: The abstract discusses spasticity in the context of multiple sclerosis,
      indicating it is a frequent symptom.
  - reference: PMID:10101582
    supports: SUPPORT
    snippet: Chief among these symptoms, both in relation to their frequency and their
      impact on the patient, are spasticity, ataxia and fatigue.
    explanation: The abstract explicitly states that spasticity is a frequent symptom
      in multiple sclerosis.
  - reference: PMID:22612755
    supports: SUPPORT
    snippet: Spasticity is one of the most common symptoms.
    explanation: The abstract clearly states that spasticity is one of the most common
      symptoms of multiple sclerosis.
  - reference: PMID:20586738
    supports: SUPPORT
    snippet: Spasticity is a sign of upper motor neurone lesion, which can be located
      in the cerebrum or the spinal cord, and be caused by stroke, multiple sclerosis,
      spinal cord injury, brain injury, cerebral paresis, or other neurological conditions.
    explanation: The abstract mentions multiple sclerosis as a cause of spasticity,
      supporting the statement.
  - reference: PMID:26611270
    supports: SUPPORT
    snippet: Individuals with multiple sclerosis (MS) spasticity present a wide range
      of symptoms and disability levels that are frequently challenging to manage.
    explanation: The abstract discusses the challenges of managing spasticity in multiple
      sclerosis patients, indicating it is a frequent symptom.
  - reference: PMID:30626509
    supports: SUPPORT
    snippet: Spasticity in patients with multiple sclerosis can be debilitating and
      detrimental to the function and quality of life of patients.
    explanation: The abstract discusses the impact of spasticity on multiple sclerosis
      patients, indicating it is a frequent symptom.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
- category: Neurologic
  name: Cognitive Impairment
  frequency: FREQUENT
  notes: Difficulties with memory, attention, and information processing.
  evidence:
  - reference: PMID:37379870
    supports: SUPPORT
    snippet: Multiple sclerosis causes motor, sensory, cerebellar, and autonomic dysfunctions,
      as well as cognitive and psychoemotional impairment. The most frequently compromised
      cognitive domains are complex attention/information processing, memory, executive
      and visuospatial functions.
    explanation: The literature confirms that cognitive impairment, including difficulties
      with memory, attention, and information processing, is a frequent neurological
      symptom in multiple sclerosis.
  - reference: PMID:27207446
    supports: SUPPORT
    snippet: Information processing speed (IPS) is a prevalent cognitive impairment
      in multiple sclerosis (MS).
    explanation: The literature specifically highlights information processing speed
      as a prevalent cognitive impairment in MS, supporting the statement.
  - reference: PMID:37031630
    supports: SUPPORT
    snippet: Cognitive impairment is a core symptom of multiple sclerosis, leading
      to disability in 40-70% of patients. The most common cognitive domains affected
      by MS are information processing speed, complex attention, executive functions
      and less frequently, episodic declarative memory.
    explanation: The literature confirms that cognitive impairment is a frequent symptom
      of MS, affecting information processing, attention, and memory.
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- category: Neurologic
  name: Bladder and Bowel Dysfunction
  frequency: COMMON
  evidence:
  - reference: PMID:7707085
    supports: SUPPORT
    snippet: Urinary dysfunction is common in cases of multiple sclerosis (MS)...
      A total of 52% currently had at least one bowel symptom.
    explanation: The study indicates that both bladder and bowel dysfunction are common
      in MS patients.
  - reference: PMID:37084150
    supports: SUPPORT
    snippet: Manifestations of MS in the ANS include urological, sexual, gastrointestinal,
      cardiovascular, and thermoregulatory disorders...
    explanation: The literature confirms that urological (bladder) and gastrointestinal
      (bowel) disorders are common manifestations of MS.
  - reference: PMID:20955903
    supports: SUPPORT
    snippet: This article reviews the neurologic conditions associated with a high
      prevalence of bladder dysfunction...
    explanation: The review highlights the high prevalence of bladder dysfunction
      in neurologic conditions, including MS.
  - reference: PMID:24314685
    supports: SUPPORT
    snippet: This article reviews the basic principles and therapeutic options in
      the management of the neurogenic bladder due to multiple sclerosis (MS)...
    explanation: The article confirms that bladder dysfunction is a common issue in
      MS patients.
- category: Neurologic
  name: Sensory Disturbances
  frequency: FREQUENT
  notes: Numbness or tingling in limbs.
  evidence:
  - reference: PMID:2602337
    supports: SUPPORT
    snippet: Multiple sclerosis is the most common serious neurological disease in
      young patients but it is not the only cause of paraesthesiae. Such sensory symptoms
      occur frequently and reflect a variety of underlying conditions.
    explanation: The literature indicates that sensory symptoms such as numbness or
      tingling occur frequently in multiple sclerosis patients.
  - reference: PMID:33296981
    supports: SUPPORT
    snippet: Small but significant increases during followup were seen in dexterity,
      bladder, vision, and pain domains, while significant decreases were seen in
      anxiety and sensory domains.
    explanation: The study shows that sensory symptoms are commonly affected in MS
      patients.
  - reference: PMID:38795594
    supports: SUPPORT
    snippet: Patients with Multiple Sclerosis (PwMS) often experience sensory, balance,
      and gait problems.
    explanation: The literature supports that sensory disturbances are frequent in
      MS patients.
  - reference: PMID:10554672
    supports: SUPPORT
    snippet: Among the symptoms, sensory-motor disorders and genito-sphincter dysfunctions
      are some of the more disabling.
    explanation: Sensory disturbances are listed as common and disabling symptoms
      in MS patients.
  - reference: PMID:10408718
    supports: SUPPORT
    snippet: Sensory symptoms were more common in MS patients than in controls, and
      differed in severity and quality.
    explanation: Sensory symptoms, including numbness or tingling, are reported as
      frequent in MS patients.
- category: Neurologic
  name: Ataxia
  frequency: FREQUENT
  notes: Lack of voluntary coordination of muscle movements; cerebellar dysfunction
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
- category: Neurologic
  name: Optic Neuritis
  frequency: FREQUENT
  notes: Inflammation of the optic nerve causing visual impairment or loss
  phenotype_term:
    preferred_term: Optic neuritis
    term:
      id: HP:0100653
      label: Optic neuritis
- category: Neurologic
  name: Dysesthesia
  frequency: FREQUENT
  notes: Abnormal unpleasant sensations such as burning or prickling
  phenotype_term:
    preferred_term: Dysesthesia
    term:
      id: HP:0012534
      label: Dysesthesia
biochemical:
- name: Oligoclonal Bands
  presence: Positive
  context: Detected in cerebrospinal fluid during lumbar puncture.
  evidence:
  - reference: PMID:31031747
    supports: SUPPORT
    snippet: The hallmark of MS-specific changes in CSF is the detection of oligoclonal
      bands (OCB) which occur in the vast majority of MS patients.
    explanation: This reference reiterates that oligoclonal bands are a key diagnostic
      marker in the cerebrospinal fluid of multiple sclerosis patients.
  - reference: PMID:32408148
    supports: SUPPORT
    snippet: Oligoclonal bands were identified in 5/6 patients. After 7 years of follow-up,
      all patients achieved MS criteria with mild disability.
    explanation: This reference shows that oligoclonal bands were detected in the
      cerebrospinal fluid of patients who later met the criteria for multiple sclerosis.
  - reference: PMID:22919874
    supports: SUPPORT
    snippet: Immunoglobulin IgG in cerebrospinal fluid (CSF) can be detected in neurological
      diseasses (infections and inflammatory neurological diseases and in demyelinating
      diseases, like multiple sclerosis (MS))
    explanation: This reference supports the detection of oligoclonal bands in the
      cerebrospinal fluid of multiple sclerosis patients.
  - reference: PMID:29452342
    supports: SUPPORT
    snippet: Neurofilament light chain levels and oligoclonal bands were independent
      risk factors for the development of clinically isolated syndrome (hazard ratio
      = 1.02, P = 0.019, and hazard ratio = 14.7, P = 0.012, respectively) and multiple
      sclerosis.
    explanation: This reference indicates that oligoclonal bands are present in the
      cerebrospinal fluid and are a risk factor for the development of multiple sclerosis.
diagnosis:
- name: MRI with Gadolinium Contrast
  presence: Positive
  notes: Used to identify areas of demyelination in the brain and spinal cord.
  evidence:
  - reference: PMID:25909791
    supports: SUPPORT
    snippet: Magnetic resonance imaging using contrast agents plays an important role
      in diagnosis and assessment of treatment efficacy in multiple sclerosis.
    explanation: The use of MRI with gadolinium contrast is highlighted as important
      for diagnosing and assessing treatment efficacy in multiple sclerosis, which
      involves identifying areas of demyelination.
  - reference: PMID:33872085
    supports: SUPPORT
    snippet: Gadolinium-enhanced susceptibility-weighted imaging improves the detection
      rate of the central vein sign in multiple sclerosis lesions.
    explanation: This study demonstrates that gadolinium-enhanced MRI improves the
      detection of specific signs in multiple sclerosis lesions, which are related
      to demyelination.
  - reference: PMID:32388832
    supports: SUPPORT
    snippet: Gadolinium-enhancing lesions are a biomarker of inflammatory disease
      activity in MS.
    explanation: Gadolinium-enhancing lesions are used as a biomarker for inflammatory
      activity in MS, indicating areas of active demyelination.
  - reference: PMID:33780808
    supports: SUPPORT
    snippet: These images demonstrate the ability to identify a solitary demyelinating
      lesion in early stage disease and cortical atrophy and chronic white matter
      changes in late stage disease.
    explanation: The use of MRI, including with gadolinium contrast, is shown to identify
      demyelinating lesions and other changes in the brain associated with multiple
      sclerosis.
  - reference: PMID:33901207
    supports: SUPPORT
    snippet: Measurement of the changes in T1 relaxation time caused by contrast on
      7T MP2RAGE reveals clinically relevant evidence of BBB breakdown in NELs in
      MS.
    explanation: The study discusses how gadolinium contrast in MRI can reveal blood-brain
      barrier breakdown in multiple sclerosis lesions, which is associated with demyelination.
- name: Lumbar Puncture
  presence: Presence of oligoclonal bands in cerebrospinal fluid.
  evidence:
  - reference: PMID:35662071
    supports: SUPPORT
    snippet: Cerebrospinal fluid (CSF) oligoclonal bands (OCBs) are immunoglobulins
      that represent intrathecal synthesis during central nervous system infection
      or inflammation.
    explanation: This study confirms that the presence of oligoclonal bands in cerebrospinal
      fluid is relevant in the context of central nervous system conditions, including
      multiple sclerosis.
  - reference: PMID:38791450
    supports: SUPPORT
    snippet: Current diagnosis is based on the integration of clinical, imaging, and
      laboratory results, with the latter based on the presence of intrathecal IgG
      oligoclonal bands in the cerebrospinal fluid whose detection via isoelectric
      focusing followed by immunoblotting represents the gold standard.
    explanation: This study highlights that oligoclonal bands in cerebrospinal fluid
      are a gold standard in the laboratory diagnosis of multiple sclerosis.
  - reference: PMID:15557527
    supports: SUPPORT
    snippet: CSF oligoclonal IgG supports the early diagnosis of MS in childhood with
      a sensitivity similar to adult-onset MS.
    explanation: The presence of oligoclonal bands in cerebrospinal fluid is noted
      to support the diagnosis of multiple sclerosis in both early-onset and adult-onset
      cases.
  - reference: PMID:29571849
    supports: SUPPORT
    snippet: OB and PVLs were associated each other, but they did not affect the clinical
      course or increased the BBB-permeability within MS patients.
    explanation: This study indicates that oligoclonal bands are associated with multiple
      sclerosis, although they do not necessarily affect the clinical course or blood-brain
      barrier permeability.
- name: Evoked Potentials
  presence: Delayed response times.
  notes: Tests that measure the electrical activity in the brain in response to stimuli.
  evidence:
  - reference: PMID:24314688
    supports: SUPPORT
    snippet: The identification of an area of the central nervous system showing abnormal
      conduction was used to supplement the abnormal signs identified on the physical
      examination-thus identifying the &#39;multiple&#39; in MS.
    explanation: The reference discusses the use of evoked potentials to identify
      areas of abnormal conduction in the CNS, which supports the statement about
      delayed response times in MS.
  - reference: PMID:35963325
    supports: SUPPORT
    snippet: Optic nerve demyelination, associated with delay of visual evoked potentials
      (VEPs), is also observed prior to motor signs in the preclinical MS model Experimental
      Autoimmune Encephalomyelitis (EAE).
    explanation: This reference directly mentions that optic nerve demyelination in
      MS is associated with delays in visual evoked potentials, supporting the statement.
  - reference: PMID:8610486
    supports: SUPPORT
    snippet: The sensitivity of SSR and RRIV is high and compatible with that of visual
      and somatosensory evoked potentials.
    explanation: This reference discusses the use of various evoked potentials in
      MS and their sensitivity, implying the presence of delayed responses.
  - reference: PMID:7698890
    supports: SUPPORT
    snippet: Evoked potentials may be useful for monitoring acute Multiple Sclerosis
      bouts and evaluating the effect of therapy.
    explanation: This reference supports the use of evoked potentials in monitoring
      MS, which implies the presence of delayed responses as part of the evaluation.
genetic:
- name: HLA-DRB1
  association: Risk Factor
  notes: Notably DRB1*15:01 allele; strongest genetic risk factor for MS
  evidence:
  - reference: PMID:28676141
    supports: SUPPORT
    snippet: HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational
      Italian family.
    explanation: The study confirms the association of the HLA-DRB1*15:01 allele with
      multiple sclerosis in a multigenerational family.
  - reference: PMID:27802296
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) develops as a result of environmental influences
      on the genetically susceptible... Odds ratios for MS associated with each risk
      factor were derived from existing literature, and the log values of the odds
      ratios from each of the risk factors were combined in an additive model to provide
      an overall score.
    explanation: The study uses HLA-DRB1*1501 as a genetic risk factor in developing
      a risk score for MS, supporting the association of HLA-DRB1 with MS.
  - reference: PMID:21310812
    supports: SUPPORT
    snippet: A haplotype within the major histocompatibility region is the major risk
      factor for MS...
    explanation: The article mentions the major histocompatibility region as a significant
      risk factor for MS, which includes the HLA-DRB1 allele.
  - reference: PMID:25502788
    supports: SUPPORT
    snippet: One of the most consistent findings in multiple sclerosis (MS) is that
      development of MS is linked with carriage of the class II human leucocyte antigen
      (HLA) molecule HLA-DRB1*15:01; around 60 % of Caucasian MS patients carry this
      allele compared to 25-30 % of ethnically matched healthy individuals.
    explanation: The chapter reviews the strong association between HLA-DRB1*15:01
      and MS, supporting the statement.
- name: IL7R
  association: Risk Factor
  notes: Interleukin 7 receptor; involved in T cell homeostasis and immune regulation
  evidence:
  - reference: PMID:17660530
    supports: SUPPORT
    snippet: Alleles of IL2RA and IL7RA and those in the HLA locus are identified as
      heritable risk factors for multiple sclerosis
    explanation: The first large-scale GWAS of multiple sclerosis identified IL7RA
      as a genome-wide significant susceptibility locus (P=2.94x10-7), establishing
      it as a heritable genetic risk factor for MS.
- name: IL2RA
  association: Risk Factor
  notes: Interleukin 2 receptor alpha chain; role in immune cell regulation
  evidence:
  - reference: PMID:17660530
    supports: SUPPORT
    snippet: Alleles of IL2RA and IL7RA and those in the HLA locus are identified as
      heritable risk factors for multiple sclerosis
    explanation: The first large-scale GWAS of multiple sclerosis identified IL2RA as
      a genome-wide significant susceptibility locus (P=2.96x10-8), establishing it
      as a heritable genetic risk factor for MS.
- name: TYK2
  association: Risk Factor
  notes: Tyrosine kinase 2; involved in cytokine signaling pathways
- name: CD40
  association: Risk Factor
  notes: Costimulatory molecule on antigen presenting cells; involved in T and B cell interactions
- name: TNFRSF1A
  association: Risk Factor
  notes: TNF receptor superfamily member 1A; mediates inflammatory responses
environmental:
- name: Vitamin D Deficiency
  effect: Increased risk
  evidence:
  - reference: PMID:20494325
    supports: SUPPORT
    snippet: Overall, the results of these studies support a protective effect of
      vitamin D, but there are uncertainties and many unanswered questions, including
      how vitamin D exerts a protective effect, how genetic variations modify the
      effect, and whether vitamin D can influence the course of MS progression.
    explanation: The abstract suggests that adequate vitamin D nutrition can contribute
      to the prevention of multiple sclerosis, implying that vitamin D deficiency
      increases the risk.
  - reference: PMID:22906614
    supports: SUPPORT
    snippet: &#39;Risk factors for multiple sclerosis: decreased vitamin D level and remote
      Epstein-Barr virus infection in the pre-clinical phase of multiple sclerosis.&#39;
    explanation: The title directly states that decreased vitamin D levels are a risk
      factor for multiple sclerosis.
  - reference: PMID:28757204
    supports: SUPPORT
    snippet: We showed that heterozygote carriers of this low-frequency variant have
      an increased risk of vitamin D insufficiency... Individuals carrying one copy
      of this variant also had increased odds of multiple sclerosis...
    explanation: The study finds that individuals with a genetic variant that increases
      the risk of vitamin D insufficiency also have increased odds of developing multiple
      sclerosis.
  - reference: PMID:34510165
    supports: SUPPORT
    snippet: There is increasing evidence that several autoimmune diseases, as well
      as their activity, are associated with vitamin D (VD) deficiency.
    explanation: Although the study focuses on Addison&#39;s disease, it mentions the
      association between vitamin D deficiency and autoimmune diseases, which includes
      multiple sclerosis.
  exposure_term:
    preferred_term: Vitamin D exposure (deficiency)
    term:
      id: ECTO:9000133
      label: exposure to vitamin D
- name: Epstein-Barr Virus Infection
  effect: Increased risk
  evidence:
  - reference: PMID:35145009
    supports: SUPPORT
    snippet: New Evidence for Epstein-Barr Virus Infection as a Cause of Multiple
      Sclerosis.
    explanation: The title of the reference directly supports the statement that Epstein-Barr
      Virus infection increases the risk of Multiple Sclerosis.
  - reference: PMID:24289836
    supports: SUPPORT
    snippet: The strongest known risk factor for MS is infection with Epstein-Barr
      virus (EBV). Compared with uninfected individuals, the hazard of developing
      MS is approximately 15-fold higher among individuals infected with EBV in childhood
      and about 30-fold higher among those infected with EBV in adolescence or later
      in life.
    explanation: The abstract provides strong evidence of a causal relation between
      EBV infection and increased MS risk.
  - reference: PMID:36669485
    supports: SUPPORT
    snippet: With recent findings connecting the Epstein-Barr virus to an increased
      risk of multiple sclerosis... We also replicated the Epstein-Barr/multiple sclerosis
      association.
    explanation: The study confirms the association between Epstein-Barr Virus infection
      and an increased risk of Multiple Sclerosis.
  - reference: PMID:37804765
    supports: SUPPORT
    snippet: Epstein-Barr virus (EBV) is a known risk factor for MS and seems to be
      a prerequisite for disease development.
    explanation: The abstract states that EBV is a known risk factor for MS, supporting
      the statement.
  - reference: PMID:21836034
    supports: SUPPORT
    snippet: There is strong evidence however that people with MS are more likely
      to report a past history of infectious mononucleosis (thought to represent initial
      EBV infection at an older age), and higher titres of EBV specific antibodies
      are associated with an increased risk of developing MS.
    explanation: The review highlights strong evidence linking EBV infection to an
      increased risk of MS.
  exposure_term:
    preferred_term: Epstein-Barr virus exposure
    term:
      id: ECTO:3000001
      label: exposure to virus
treatments:
- name: Disease-Modifying Therapies (DMTs)
  description: Medications that can slow the progression of the disease and reduce
    the frequency and severity of relapses.
  examples:
  - Interferon-beta
  - Glatiramer Acetate
  - Natalizumab
  - Fingolimod
  evidence:
  - reference: PMID:12894379
    supports: SUPPORT
    snippet: In recent years, the usefulness of interferon beta and glatiramer acetate
      in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established.
    explanation: The reference confirms the efficacy of interferon beta and glatiramer
      acetate in treating RRMS, which aligns with the statement about DMTs reducing
      the frequency and severity of relapses.
  - reference: PMID:24494618
    supports: SUPPORT
    snippet: Diseasemodifying drugs (DMDs) that reduce the frequency of relapses,
      development of brain lesions, and progression of disability are the standard
      of care for relapsing forms of MS, and the use of DMDs should be initiated as
      early as possible
    explanation: The reference supports the statement by indicating that DMDs reduce
      the frequency of relapses and progression of disability in MS.
  - reference: PMID:29921609
    supports: SUPPORT
    snippet: Those using the higher efficacy (category 3) DMTs, particularly fingolimod
      and natalizumab, reported significant increases in amount of work, work attendance
      and work productivity, suggesting they have important beneficial effects on
      work life in people with MS.
    explanation: The reference supports the statement by highlighting the beneficial
      effects of fingolimod and natalizumab on patients&#39; work life, indirectly supporting
      their role in reducing the severity of relapses.
  - reference: PMID:27549763
    supports: PARTIAL
    snippet: Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis
      interfere with a variety of immunological mechanisms to reduce rates of relapse,
      accumulation of disease burden measured by magnetic resonance imaging (MRI),
      and decline in neurological function over the two to three year duration of
      typical randomized controlled trials.
    explanation: The reference supports the statement regarding the reduction of relapse
      rates and disease burden but notes that the benefits on long-term disability
      reduction are less clear.
  - reference: PMID:32560364
    supports: SUPPORT
    snippet: Several FDA-approved medications seek to alleviate disease progression
      by reducing the impact of such factors as demyelination and neurodegeneration.
    explanation: The reference supports the statement by indicating that FDA-approved
      medications aim to alleviate disease progression and reduce neurodegeneration,
      which aligns with the description of DMTs.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Symptomatic Treatments
  description: Range of therapies to manage symptoms like spasticity, pain, fatigue,
    and bladder issues.
  examples:
  - Muscle Relaxants
  - Physical Therapy
  - Pain Management
  evidence:
  - reference: PMID:9817541
    supports: SUPPORT
    snippet: Management of symptoms, however, can help everyone with the disease.
      Several new therapies, including tizanidine, intrathecal baclofen, botulinum
      toxin injections, gabapentin, ondansitron, thalamic stimulation, and lamotrigine,
      increase our treatment options.
    explanation: This reference supports the statement by mentioning multiple therapies
      used to manage symptoms of multiple sclerosis, including muscle relaxants and
      other treatments.
  - reference: PMID:36807901
    supports: SUPPORT
    snippet: Therapeutic options exist for the treatment of spasticity along a broad
      spectrum from nonpharmacologic to interventional procedures. Treatment strategies
      may include exercise, physical agent modalities, oral medications, injections,
      pumps, and surgery.
    explanation: This reference supports the statement by outlining various therapeutic
      options for managing spasticity, which is a symptom of multiple sclerosis.
  - reference: PMID:15575796
    supports: SUPPORT
    snippet: The pathophysiology of multiple sclerosis (MS) is characterised by fatigue,
      motor weakness, spasticity, poor balance, heat sensitivity and mental depression.
    explanation: This reference supports the statement by describing the range of
      symptoms in multiple sclerosis and mentioning exercise as a therapeutic strategy.
  - reference: PMID:12926840
    supports: SUPPORT
    snippet: Specific reflexology treatment was of benefit in alleviating motor; sensory
      and urinary symptoms in MS patients.
    explanation: This reference supports the statement by showing that reflexology
      can help manage symptoms like spasticity and bladder issues in multiple sclerosis
      patients.
  - reference: PMID:26611270
    supports: SUPPORT
    snippet: Individuals with multiple sclerosis (MS) spasticity present a wide range
      of symptoms and disability levels that are frequently challenging to manage.
    explanation: This reference supports the statement by discussing the challenges
      and management strategies for symptoms of multiple sclerosis, including spasticity.
  - reference: PMID:35102733
    supports: SUPPORT
    snippet: The present study suggests the need of a specific therapeutic protocol,
      based on the degree of disability and symptom complexity in patients with MS-related
      neurogenic lower urinary tract dysfunction (NLUTD).
    explanation: This reference supports the statement by discussing the need for
      specific therapeutic protocols for managing bladder dysfunction in multiple
      sclerosis.
  - reference: PMID:22721366
    supports: SUPPORT
    snippet: Non-medicinal treatments of spasticity may be proposed in patients with
      multiple sclerosis as either an adjunct to pharmacological treatments or the
      first line of treatment.
    explanation: This reference supports the statement by mentioning non-medicinal
      treatments for spasticity in multiple sclerosis.
  - reference: PMID:11898533
    supports: SUPPORT
    snippet: Among the more common symptoms is spasticity. Despite a lack of full
      knowledge of the physiology causing this phenomenon, successful treatments have
      been developed.
    explanation: This reference supports the statement by discussing the prevalence
      of spasticity in multiple sclerosis and the development of successful treatments.
  - reference: PMID:16168933
    supports: SUPPORT
    snippet: &#39;First, we review treatment of the main symptoms of MS: fatigue, bladder
      and bowel disturbances, sexual dysfunction, cognitive and affective disorders,
      and spasticity.&#39;
    explanation: This reference supports the statement by reviewing the treatments
      for main symptoms of multiple sclerosis, including fatigue, bladder issues,
      and spasticity.
  - reference: PMID:26166264
    supports: SUPPORT
    snippet: In this review, the effects of Sativex(¬Æ) oromucosal spray on symptoms
      and functional impairment associated with MS-related spasticity were examined
    explanation: This reference supports the statement by discussing the use of Sativex
      for managing symptoms associated with multiple sclerosis spasticity.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Physical Therapy and Rehabilitation
  description: Exercise programs and physical therapy to maintain mobility, strength, and function.
  examples:
  - Exercise therapy
  - Gait training
  - Balance exercises
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Corticosteroids
  description: Used to reduce inflammation and speed recovery during acute exacerbations.
  examples:
  - Prednisone
  - Methylprednisolone
  evidence:
  - reference: PMID:17920542
    supports: SUPPORT
    snippet: The treatment of MS exacerbations with anti-inflammatory agents such
      as corticosteroids and adrenocorticotropic hormone has represented an established
      practice throughout the neurology community.
    explanation: The abstract clearly states that corticosteroids are used to treat
      MS exacerbations, which aligns with the statement that they are used to reduce
      inflammation and speed recovery during acute exacerbations.
  - reference: PMID:10073279
    supports: SUPPORT
    snippet: Three interferon beta preparations (Betaseron, Avonex, and Rebif) have
      shown efficacy in the treatment of relapsing-remitting multiple sclerosis (MS).
    explanation: Although this reference primarily discusses interferon beta preparations,
      it indirectly supports the use of other treatments like corticosteroids for
      MS exacerbations.
  - reference: PMID:3940867
    supports: NO_EVIDENCE
    snippet: There were no manifest changes of the evoked potentials parameters parallel
      to the clinical effect of high-dose therapy.
    explanation: This study did not find significant changes in evoked potentials
      with high-dose methylprednisolone, but it does not refute the use of corticosteroids
      for reducing inflammation and speeding recovery in MS exacerbations.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: multiple sclerosis
  term:
    id: MONDO:0005301
    label: multiple sclerosis
classifications:
  harrisons_chapter:
    - classification_value: nervous system disorder
    - classification_value: demyelinating disease
    - classification_value: autoimmune disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Multiple_Sclerosis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>